Neumirna Therapeutics ApS
Private limited companyCVR 41696451København SVActive
Neumirna Therapeutics ApS is a private limited company, based in København SV, active in research and experimental development on natural sciences and engineering, founded in 2020. The company made a loss in both 2024 and 2025, most recently DKK 55.8m.
Key figures · financial year 2025
Gross profit−DKK 53.9m−880% vs. 2024
Net profit−DKK 55.8m−702.2% vs. 2024
EquityDKK 91.8m+598.4% vs. 2024
Employees11latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss grew: from DKK 7m to DKK 55.8m (2024 → 2025).
- Equity turned positive again: DKK 91.8m (2024 → 2025).
Management and owners, last 24 months
- New in management: Luis Garcia Pareras (chair of the board, 10/01/2025), Andreas Wallnöfer (board member, 24/03/2025) and Ellen Kinson Donnelly (ceo, 15/09/2025) (+3).
- Stepped down: Markus Sakari Kauppinen (board member, 10/01/2025), Lars Hellerung Christiansen (board member, 10/01/2025) and Sten Verland (chair of the board, 10/01/2025) (+3).
- New owners registered: Hellerung ApS (15/05/2025), Innovestor Life Science Fund Ky (15/05/2025) and Invivo Ventures Iii, Fcre (11/08/2025) (+7).
- No longer registered as owner: Hellerung ApS (14/05/2025), Fonden for Syddansk Vækstfremme (10/01/2025) and Krudtmøllen I ApS (10/01/2025) (+9).
Registrations, last 24 months
- 30/09/2026: Share capital changed from 193,816 DKK to 195,256 DKK
- 11/08/2025: Share capital changed from 132,144 DKK to 193,816 DKK
- 15/05/2025: Share capital changed from 106,914 DKK to 132,144 DKK
- 10/01/2025: Share capital changed from 48,820 DKK to 106,914 DKK
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2021–2025 · amounts in DKK thousandEquity and net profit
| 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | −5,781 | −4,661 | −5,476 | −5,496 | −53,860 | −880% |
| Operating profit (EBIT) | – | – | – | – | −61,865 | – |
| Profit before tax | −7,615 | −6,780 | −9,745 | −8,719 | −61,286 | −602.9% |
| Net profit | −6,068 | −5,292 | −8,034 | −6,954 | −55,786 | −702.2% |
| Total assets | 5,746 | 8,972 | 6,255 | 5,507 | 100,357 | +1,722.5% |
| Equity | 1,859 | −3,434 | −11,468 | −18,422 | 91,816 | +598.4% |
| Liabilities | 3,887 | 12,406 | 17,723 | 23,929 | – | – |
| Cash and cash equivalents | 4,033 | 7,191 | 3,850 | 3,011 | 88,753 | +2,847.7% |
| Average number of employees | 2 | 3 | 3 | 5 | 10 | +100% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 5 years in a row
Net result has been negative in 2021–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
5 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 29/06/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 03/07/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 07/05/2024 | The company | PDFXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 21/05/2023 | The company | PDFXBRL |
| 2021 | 21/09/2020 – 31/12/2021 | 01/06/2022 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Gross profit−DKK 53.9mNo. 416 of 421
Better than 1% of the companies in the industry
EquityDKK 91.8mNo. 37 of 431
Better than 92% of the companies in the industry
Number of employees11No. 142 of 431
Better than 67% of the companies in the industry
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 69,730of 69,742 Better than 0% | No. 1,927of 69,964 Better than 97% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 322of 323 Better than 0% | No. 5of 329 Better than 99% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 33,575of 33,588 Better than 0% | No. 736of 33,687 Better than 98% |
| All companies of type ApS66,508 companies in the comparison | No. 66,368of 66,379 Better than 0% | No. 1,228of 66,505 Better than 98% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineeringGross profit
- Neumirna Therapeutics ApS−DKK 53.9m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
Net profit
- Neumirna Therapeutics ApS−DKK 55.8m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
Equity
- Neumirna Therapeutics ApSDKK 91.8m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
Employees
- Neumirna Therapeutics ApS11
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
- Hellerung ApS25%
- Innovestor Life Science Fund Ky15%
- Invivo Ventures Iii, Fcre10%
- Angelini Ventures S.p.A.15%
Neumirna Therapeutics ApS
Management
7 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Ellen Kinson Donnelly | CEO | 15/09/2025 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Henrik Valdemar Klitgaard | Board member | 21/09/2020 |
| Milla Koistinaho | Board member | 02/01/2023 |
| Luis Garcia Pareras | Chair of the board | 10/01/2025 |
| Andreas Wallnöfer | Board member | 24/03/2025 |
| Ellen Kinson Donnelly | Board member | 15/09/2025 |
| Francesco Paolo Di Giorgio | Board member | 07/04/2026 |
- Founders
- Hellerung ApS, Fonden for Syddansk Vækstfremme, Krudtmøllen I ApS, Henrik Valdemar Klitgaard Holding ApS, Pandion Holding ApS
Former management (12)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Mads Spangaard Rasmussen | Board member | 21/09/2020 | 17/06/2021 |
| Markus Sakari Kauppinen | Board member | 21/09/2020 | 10/01/2025 |
| Lars Hellerung Christiansen | Chair of the board | 21/09/2020 | 10/12/2020 |
| Morten Priskorn | Board member | 21/09/2020 | 12/10/2021 |
| Henrik Valdemar Klitgaard | CEO | 21/09/2020 | 01/11/2023 |
| Lars Hellerung Christiansen | Board member | 11/12/2020 | 10/01/2025 |
| Wyle Solomon | Chair of the board | 11/12/2020 | 18/06/2021 |
| Mads Spangaard Rasmussen | Chair of the board | 18/06/2021 | 08/11/2022 |
| Sten Verland | Chair of the board | 09/11/2022 | 10/01/2025 |
| Mads Spangaard Rasmussen | Board member | 09/11/2022 | 10/01/2025 |
| Janine Terra Erler | CEO | 01/11/2023 | 15/09/2025 |
| Thomas Michael Thestrup | Board member | 10/01/2025 | 07/04/2026 |
Signing rule: Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af den samlede bestyrelse.
Address and production units
1 active production unitsA.C. Meyers Vænge 15
2450 København SV
København Municipality · Postcode 2450
Other companies at the address (1)
- Silkroad Studios ApSComputer programming activities
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Neumirna Therapeutics ApS | A.C. Meyers Vænge 15, 2450 København SV | 11 | 1026284798 |
Purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
The purpose is quoted from the register in Danish.
Changes year by year
72 registered events172020
52021
42022
42023
12024
372025
42026
20264 changescapital 1 · accounts 1 · management 2
- CapitalShare capital changed from 193,816 DKK to 195,256 DKK
- AccountsAnnual report for 2025 published
- ManagementFrancesco Paolo Di Giorgio appointed board member
- ManagementThomas Michael Thestrup stepped down as board member
202537 changesmanagement 10 · capital 3 · ownership 22 · accounts 1 · industry 1
- ManagementEllen Kinson Donnelly appointed ceo
- ManagementEllen Kinson Donnelly appointed board member
- ManagementJanine Terra Erler stepped down as ceo
- CapitalShare capital changed from 132,144 DKK to 193,816 DKK
- OwnershipAngelini Ventures S.p.A. registered as owner (15%)
- OwnershipINVIVO VENTURES III, FCRE registered as owner (10%)
- OwnershipPandion Holding ApS is no longer registered as owner
- OwnershipAngelini Ventures S.p.A. is no longer registered as owner
- OwnershipINVIVO VENTURES III, FCRE is no longer registered as owner
- AccountsAnnual report for 2024 published
- CapitalShare capital changed from 106,914 DKK to 132,144 DKK
- OwnershipAngelini Ventures S.p.A. registered as owner (10%)
- OwnershipInnovestor Life Science Fund Ky registered as owner (15%)
- OwnershipHELLERUNG ApS registered as owner (25%)
- OwnershipHenrik Valdemar Klitgaard Holding ApS is no longer registered as owner
- OwnershipInnovestor Life Science Fund Ky is no longer registered as owner
- OwnershipAngelini Ventures S.p.A. is no longer registered as owner
- OwnershipHELLERUNG ApS is no longer registered as owner
- ManagementAndreas Wallnöfer appointed board member
- CapitalShare capital changed from 48,820 DKK to 106,914 DKK
- ManagementLuis Garcia Pareras appointed chair of the board
- ManagementThomas Michael Thestrup appointed board member
- ManagementMads Spangaard Rasmussen stepped down as board member
- ManagementSten Verland stepped down as chair of the board
- ManagementLars Hellerung Christiansen stepped down as board member
- ManagementMarkus Sakari Kauppinen stepped down as board member
- OwnershipINVIVO VENTURES III, FCRE registered as owner (5%)
- OwnershipHenrik Valdemar Klitgaard Holding ApS registered as owner (5%)
- OwnershipPandion Holding ApS registered as owner (5%)
- OwnershipInnovestor Life Science Fund Ky registered as owner (10%)
- OwnershipAngelini Ventures S.p.A. registered as owner (5%)
- OwnershipWyle Solomon is no longer registered as owner
- OwnershipFONDEN FOR SYDDANSK VÆKSTFREMME is no longer registered as owner
- OwnershipKrudtmøllen I ApS is no longer registered as owner
- OwnershipPandion Holding ApS is no longer registered as owner
- OwnershipHenrik Valdemar Klitgaard Holding ApS is no longer registered as owner
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changeaccounts 1
- AccountsAnnual report for 2023 published
20234 changesmanagement 3 · accounts 1
- ManagementJanine Terra Erler appointed ceo
- ManagementHenrik Valdemar Klitgaard stepped down as ceo
- AccountsAnnual report for 2022 published
- ManagementMilla Koistinaho appointed board member
20224 changesmanagement 3 · accounts 1
- ManagementMads Spangaard Rasmussen appointed board member
- ManagementSten Verland appointed chair of the board
- ManagementMads Spangaard Rasmussen stepped down as chair of the board
- AccountsAnnual report for 2021 published
20215 changescapital 1 · management 4
- CapitalShare capital changed from 40,000 DKK to 48,820 DKK
- ManagementMorten Priskorn stepped down as board member
- ManagementMads Spangaard Rasmussen appointed chair of the board
- ManagementWyle Solomon stepped down as chair of the board
- ManagementMads Spangaard Rasmussen stepped down as board member
202017 changesmanagement 9 · ownership 6 · address 1 · founded 1
- ManagementWyle Solomon appointed chair of the board
- ManagementLars Hellerung Christiansen appointed board member
- ManagementLars Hellerung Christiansen stepped down as chair of the board
- OwnershipWyle Solomon registered as owner (5%)
- AddressMoved to A.C. Meyers Vænge 15, 2450 København SV
- FoundedRegistered as Neumirna Therapeutics ApS
- ManagementMorten Priskorn appointed board member
- ManagementLars Hellerung Christiansen appointed chair of the board
- ManagementMads Spangaard Rasmussen appointed board member
- ManagementMarkus Sakari Kauppinen appointed board member
- ManagementHenrik Valdemar Klitgaard appointed board member
- ManagementHenrik Valdemar Klitgaard appointed ceo
- OwnershipFONDEN FOR SYDDANSK VÆKSTFREMME registered as owner (5%)
- OwnershipPandion Holding ApS registered as owner (15%)
- OwnershipHenrik Valdemar Klitgaard Holding ApS registered as owner (10%)
- OwnershipHELLERUNG ApS registered as owner (33.33%)
- OwnershipKrudtmøllen I ApS registered as owner (5%)
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Same people in management
- NTG Nordic Transport Group A/Svia Morten Priskorn
- Taconic Biosciences A/Svia Sten Verland
- Glycom A/Svia Sten Verland
- Scanbur A/Svia Sten Verland
- MedTrace Pharma A/Svia Mads Spangaard Rasmussen
- Advalight ApSvia Mads Spangaard Rasmussen
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.